Brooklynn Gasser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Brooklynn Gasser has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Meghan C. Towne
Medical Affairs Ambry Genetics Aliso Viejo California USA
2 shared publications - Amanda Connors
Division of Maternal‐Fetal Medicine Lehigh Valley Health Network Allentown Pennsylvania USA
1 shared publication - Amélie Cordovado
Institut de neurosciences cognitives et intégratives d’Aquitaine (INCIA), CNRS, École pratique des hautes études (EPHE), UMR5287, Université de Bordeaux
1 shared publication - Anne-Sophie Denommé-Pichon
Université Bourgogne Europe, CHU Dijon Bourgogne, Laboratoire de Génomique Médicale, FHU-TRANSLAD, Centre de recherche Translationnelle en Médecine moléculaire - Inserm UMR1231 équipe GAD, Dijon, France
1 shared publication - Annick Toutain
Department of Genetics, Bretonneau University Hospital, Tours, France
1 shared publication Antonio Vitobello
INSERM, Unit 1231 GAD Team, Burgundy University, Dijon, France
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in Prenatal Diagnosis
Prenatal Syndromic Presentation of Novel Biallelic ARFGEF1 Variants Involves Congenital Skeletal Defects, Growth Restriction, and Brain Anomalies
- 13 November 2026
- Published by Wiley in Prenatal Diagnosis
Open AccessPrenatal Syndromic Presentation of Novel Biallelic ARFGEF1 Variants Involves Congenital Skeletal Defects, Growth Restriction, and Brain Anomalies
- Open Access
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Utility of Targeted RNA Analysis in Neurogenetic Disorders
Clinical genetic testing is a powerful diagnostic tool for neurologic disorders. However, its clinical utility is diminished by the large number of variants of unknown significance (VUS) detected in patients. While in silico predictive tools have improved, accurate classification of potentially spliceogenic variants still requires a demonstrated splicing impact. One major challenge for RNA studies for neurogenetic conditions is the access to disease-relevant tissues for analysis. In this study, we sought to determine how RNA studies of whole-blood RNA can effectively reclassify variants in genes associated with neurologic disorders. Thirty-eight potentially spliceogenic variants based on location and/or in silico predictions were identified in patients who underwent genetic testing (single gene, multigene panel, or exome) for a neurologic phenotype. These included 26 intronic (4 canonical and 22 noncanonical) and 12 exonic (8 missense, 2 nonsense, and 2 synonymous) variants. RNA isolated from the whole blood of the patients and healthy controls underwent targeted RT-PCR sequencing. Variants were assessed pre-RNA and post-RNA analysis based on the ACMG/AMP standards and guidelines. In addition, we reviewed the whole blood expression levels, based on the Genotype Tissue Expression (GTEx) Portal, for 212 genes commonly ordered for neurodevelopmental clinical genetic testing. RNA analysis led to reclassification of 79% (30/38) of the variants. Eighteen variants became diagnostic (i. e., VUS to pathogenic or likely pathogenic), and one likely pathogenic was upgraded to pathogenic. Eleven variants were downgraded to likely benign. The remaining variants did not change classification due to inconclusive RNA data (N = 3) or availability and/or strength of other lines of evidence (N = 5). Based on the GTEx expression data, 77% (164/212) of commonly ordered neurodevelopmental genes had expression in whole blood that is sufficient for targeted RNA analysis. RNA studies provided molecular evidence enabling reclassification for the majority of variants. While diagnostic reclassifications provided a genetic answer for patients, downgrades also had an important impact by resolving VUS. Our data indicate that targeted RNA analysis using whole blood clarify the pathogenicity of potentially spliceogenic variants identified in clinical genetic testing and improve the accuracy of genetic diagnoses in neurologic disorders.
- 1 April 2026
- Published by Wolters Kluwer Health in Neurology Genetics
- Vol. 12 (2)
Open AccessUtility of Targeted RNA Analysis in Neurogenetic Disorders
Clinical genetic testing is a powerful diagnostic tool for neurologic disorders. However, its clinical utility is diminished by the large number of variants of unknown significance (VUS) detected in patients. While in silico predictive tools have improved, accurate classification of potentially spliceogenic variants still requires a demonstrated splicing impact. One major challenge for RNA studies for neurogenetic conditions is the access to disease-relevant tissues for analysis. In this study, we sought to determine how RNA studies of whole-blood RNA can effectively reclassify variants in genes associated with neurologic disorders. Thirty-eight potentially spliceogenic variants based on location and/or in silico predictions were identified in patients who underwent genetic testing (single gene, multigene panel, or exome) for a neurologic phenotype. These included 26 intronic (4 canonical and 22 noncanonical) and 12 exonic (8 missense, 2 nonsense, and 2 synonymous) variants. RNA isolated from the whole blood of the patients and healthy controls underwent targeted RT-PCR sequencing. Variants were assessed pre-RNA and post-RNA analysis based on the ACMG/AMP standards and guidelines. In addition, we reviewed the whole blood expression levels, based on the Genotype Tissue Expression (GTEx) Portal, for 212 genes commonly ordered for neurodevelopmental clinical genetic testing. RNA analysis led to reclassification of 79% (30/38) of the variants. Eighteen variants became diagnostic (i. e., VUS to pathogenic or likely pathogenic), and one likely pathogenic was upgraded to pathogenic. Eleven variants were downgraded to likely benign. The remaining variants did not change classification due to inconclusive RNA data (N = 3) or availability and/or strength of other lines of evidence (N = 5). Based on the GTEx expression data, 77% (164/212) of commonly ordered neurodevelopmental genes had expression in whole blood that is sufficient for targeted RNA analysis. RNA studies provided molecular evidence enabling reclassification for the majority of variants. While diagnostic reclassifications provided a genetic answer for patients, downgrades also had an important impact by resolving VUS. Our data indicate that targeted RNA analysis using whole blood clarify the pathogenicity of potentially spliceogenic variants identified in clinical genetic testing and improve the accuracy of genetic diagnoses in neurologic disorders.
- Open Access
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 7085599
Heterozygous Missense Variants in the ATPase Phospholipid Transporting 9A Gene, ATP9A, Alter Dendritic Spine Maturation and Cause Dominantly Inherited Nonsyndromic Intellectual Disability
Intellectual disability is a neurodevelopmental disorder, affecting 2%–3% of the population, with a genetic cause in the majority of cases. ATP9A (Online Mendelian Inheritance in Man (OMIM) ∗609126, NM_006045.3) has recently been added to the list of candidate genes involved in this disorder with the identification of biallelic truncating variants in patients with a neurodevelopmental disorder. In this study, we propose a novel mode of inheritance for ATP9A‐related disorders with the identification of five de novo heterozygous missense variants (p.(Thr393Arg), p.(Glu400Gln), p.(Lys461Glu), p.(Gly552Ala), and p.(His713Asp)), in patients with intellectual disability. In a patient with a similar phenotype, we also identified two truncating variants in ATP9A (p.(Arg145 ∗), p.(Glu901 ∗)), adding a novel family to the six already described in the literature with the recessive mode of inheritance. Functional studies were performed to assess the pathogenicity of these variants. Overexpression of four selected missense mutant forms of Atp9a in HeLa cells and in primary neuronal cultures led to a loss of mature dendritic spines. In HeLa cells, the endosomal localization of the protein encoded by three of these missense variants was preserved whereas the fourth remained blocked in the endoplasmic reticulum. To mimic the effect on neuronal morphology and spine density of nonsense variants, small hairpin RNAs (shRNAs) were used. They induced a decreased expression of ATP9A, affecting the neuronal arborization by decreasing the number of dendrites per neuron. Our results therefore demonstrate the pathogenicity of ATP9A heterozygous missense variants and confirm the role of ATP9A in neuronal maturation and in brain wiring during development. They strengthen the association of ATP9A with neurodevelopmental disorders and demonstrate that a double mode of inheritance should be considered for ATP9A‐related disorders.
- 1 January 2025
- Published by Wiley in Human Mutation
- Vol. 2025 (1) , 7085599
Open AccessHeterozygous Missense Variants in the ATPase Phospholipid Transporting 9A Gene, ATP9A, Alter Dendritic Spine Maturation and Cause Dominantly Inherited Nonsyndromic Intellectual Disability
Intellectual disability is a neurodevelopmental disorder, affecting 2%–3% of the population, with a genetic cause in the majority of cases. ATP9A (Online Mendelian Inheritance in Man (OMIM) ∗609126, NM_006045.3) has recently been added to the list of candidate genes involved in this disorder with the identification of biallelic truncating variants in patients with a neurodevelopmental disorder. In this study, we propose a novel mode of inheritance for ATP9A‐related disorders with the identification of five de novo heterozygous missense variants (p.(Thr393Arg), p.(Glu400Gln), p.(Lys461Glu), p.(Gly552Ala), and p.(His713Asp)), in patients with intellectual disability. In a patient with a similar phenotype, we also identified two truncating variants in ATP9A (p.(Arg145 ∗), p.(Glu901 ∗)), adding a novel family to the six already described in the literature with the recessive mode of inheritance. Functional studies were performed to assess the pathogenicity of these variants. Overexpression of four selected missense mutant forms of Atp9a in HeLa cells and in primary neuronal cultures led to a loss of mature dendritic spines. In HeLa cells, the endosomal localization of the protein encoded by three of these missense variants was preserved whereas the fourth remained blocked in the endoplasmic reticulum. To mimic the effect on neuronal morphology and spine density of nonsense variants, small hairpin RNAs (shRNAs) were used. They induced a decreased expression of ATP9A, affecting the neuronal arborization by decreasing the number of dendrites per neuron. Our results therefore demonstrate the pathogenicity of ATP9A heterozygous missense variants and confirm the role of ATP9A in neuronal maturation and in brain wiring during development. They strengthen the association of ATP9A with neurodevelopmental disorders and demonstrate that a double mode of inheritance should be considered for ATP9A‐related disorders.